成人接种COVID-19疫苗后吉兰-巴雷综合征未显著增加:一项疫苗不良事件报告系统研究
本研究基于疫苗不良事件报告系统,采用Brighton标准判定成人接种COVID-19疫苗后吉兰-巴雷综合征(GBS)的报告率,并与同期其他疫苗接种后及对照期报告率比较。结果显示COVID-19疫苗后GBS报告率显著高于流感及其他疫苗,但处于一般人群GBS发病率范围内;自身对照分析显示风险期与对照期报告率差异显著,估计接种后6周内每百万剂次超额报告0.7-1.7例。作者认为部分GBS病例与COVID-19疫苗接种存在时间关联,需持续分析。
要点
- COVID-19疫苗后GBS报告率显著高于流感及其他疫苗,但仍在一般人群发病率范围内。
- 自身对照分析显示风险期与对照期报告率差异显著,6周内估计每百万剂次超额报告0.7-1.7例。
- 机器学习模型显示女性及18-44岁与更差结局相关,GBS发病间隔与预后无关。
核心结论
- COVID-19疫苗接种后GBS报告率与一般人群无统计学差异,但接种后6周内GBS报告增加较其他疫苗更明显,提示部分GBS病例与接种存在时间关联。
- 其他疫苗后GBS报告率较COVID-19前下降,凸显被动监测系统固有局限;这些发现需对COVID-19疫苗后GBS进行持续分析,机器学习模型需进一步改进方可用于临床。
研究设计与样本
- 研究基于疫苗不良事件报告系统,采用Brighton标准判定成人接种COVID-19疫苗后GBS,并与同期其他疫苗接种后及对照期报告率比较。
- 统计方法包括比例检验和Pearson卡方检验,并进行自身对照和病例中心分析;另用机器学习模型识别与更差结局(急诊或就诊、住院、死亡)相关的因素。
主要发现
- COVID-19疫苗后GBS报告率为每千万剂次49.7,显著高于流感疫苗的0.19和其他疫苗的0.16(p < 0.0001)。
- COVID-19疫苗后GBS报告率处于一般人群GBS发病率范围内。
- 自身对照和病例中心分析显示,COVID-19疫苗接种后风险期与对照期GBS报告率差异显著(p < 0.0001)。
- 估计COVID-19疫苗接种后6周内每百万剂次超额报告GBS 0.7-1.7例。
- 机器学习模型显示女性及18-44岁与更差结局相关;GBS发病间隔与预后无关联。
关键数值与推荐
- GBS判定采用Brighton标准。
- 更差结局定义为急诊或就诊、住院和死亡。
- COVID-19疫苗后GBS报告率为每千万剂次49.7,流感疫苗为0.19,其他疫苗为0.16(p < 0.0001)。
- 风险期与对照期报告率差异p < 0.0001;6周内每百万剂次超额报告0.7-1.7例。
临床怎么用
- 作者认为部分GBS病例与COVID-19疫苗接种存在时间关联,需对接种后GBS进行持续分析。
- 作者指出机器学习模型需进一步改进方可用于临床。
局限性
- 其他疫苗后GBS报告率较COVID-19前下降,凸显任何被动监测系统固有局限。
- 机器学习模型需进一步改进方可用于临床。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the association between Guillain-Barré syndrome (GBS) and COVID-19 vaccination. BACKGROUND: On July 13, 2021, the US Food and Drug Administration (FDA) released a new warning that Johnson & Johnson COVID-19 vaccine could increase the risk of developing GBS. METHODS: The reporting rate of adult GBS after COVID-19 vaccination, ascertained with Brighton criteria, was compared with the reporting rate after other vaccinations during the same time period, and also compared with the reporting rate during control periods. Statistical methods such as proportion tests, and Pearson's chi-squared test were utilized to identify significant relationships. Self-controlled and case centered analyses were conducted. A machine learning model was utilized to identify the factors associated with a worse outcome defined as emergency room (ER) or doctor visits, hospitalizations, and deaths. RESULTS: The reporting rate of GBS after COVID-19 vaccination was significantly higher than after influenza and other vaccinations (49.7, 0.19, 0.16 per 10 million, p < 0.0001). However, the reporting rate was within the incidence range of GBS in the general population. Using self-controlled and case centered analyses, there was a significant difference in the reporting rate of GBS after COVID-19 vaccination between the risk period and control period (p < 0.0001). There was an estimated 0.7-1.7 per million excess reports of GBS within 6 weeks of COVID-19 vaccination. Machine learning model demonstrated that female gender and age between 18 and 44 are associated with worse outcome. No association was found between the onset interval of GBS and its prognosis. CONCLUSIONS: Although the reporting rate of GBS after COVID-19 vaccination was not statistically different than that of the general population, the increased reporting of GBS within the first 6 weeks after COVID-19 vaccination, more so than with other vaccinations, suggests that some cases of GBS are temporally associated with COVID-19 vaccination. However, there is a reduction in the reporting rate of GBS after other vaccines, compared to reporting rates pre-COVID-19, highlighting limitations inherent in any passive surveillance system. These findings warrant continuous analysis of GBS after COVID-19 vaccination. Further improvement of the machine learning model is needed for clinical use.
引用
- Jaffry M, Mostafa F, Mandava K, et al. No significant increase in Guillain-Barré syndrome after COVID-19 vaccination in adults: A vaccine adverse event reporting system study. Vaccine. 2022. PMID: 36055875. doi:10.1016/j.vaccine.2022.08.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。